ASH Highlights and Commentary: Myeloid Malignancies
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus, Aurora, Colorado
J Adv Pract Oncol 2022;13(suppl 2):15-23 |
© 2022 Harborside™
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Lindsey Lyle, MS, PA-C, of University of Colorado Anschutz Medical Campus, considers promising results in the myeloid malignancies space. Ms. Lyle highlights long-term data on the combination of eprenetapopt (APR-246) and azacitidine in patients with TP53-mutated acute myeloid leukemia/myelodysplastic syndromes, a new option for patients with paroxysmal nocturnal hemoglobinuria, and valuable insights into Black and non-Black patient preferences regarding their treatment and communication with their providers.
On the JADPRO website, you’ll find several short videos on these important abstracts that the faculty members filmed on site. Visit advancedpractitioner.com/highlights to continue the experience!
For access to the full length article, please sign in